EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Palisade Bio's enterprise value is $-6.26 Mil.
Palisade Bio's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, Palisade Bio's EV-to-Revenue for today is .
The historical rank and industry rank for Palisade Bio's EV-to-Revenue or its related term are showing as below:
PALI'
s EV-to-Revenue Range Over the Past 10 Years
Min: -48.86 Med: -33.26 Max: 8.81
Current: -25.04
During the past 4 years, the highest EV-to-Revenue of Palisade Bio was 8.81. The lowest was -48.86. And the median was -33.26.
PALI's EV-to-Revenue is ranked better than 98.27% of 1038
companies
in the Biotechnology industry
Industry Median: 8.22
vs PALI: -25.04
As of today (2024-05-24), Palisade Bio's stock price is $4.91.
Palisade Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Palisade Bio's PS Ratio for today is .
Palisade Bio EV-to-Revenue Historical Data
The historical data trend for Palisade Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Palisade Bio's EV-to-Revenue
For the Biotechnology subindustry, Palisade Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Palisade Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Palisade Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Palisade Bio's EV-to-Revenue falls into.
Palisade Bio's current Enterprise Value is $-6.26 Mil.
Palisade Bio's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Palisade Bio's share price for today is $4.91.
Palisade Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Palisade Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Palisade Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PALI has been successfully added to your 